Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.

Strategies in Developing Promising Histone Deacetylase Inhibitors.

The Zinc-Dependent HDACs: Non-Histone Substrates and Catalytic Deacylation Beyond Deacetylation.

An Update On The Emerging Approaches For Histone Deacetylase (Hdac) Inhibitor Drug Discovery And Future Perspectives

Structure-Based Inhibitor Discovery Of Class I Histone Deacetylases (Hdacs)

Targeting histone deacetylases: Emerging applications beyond cancer

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

HDAC8 as a target in drug discovery: Function, structure and design

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions

Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases

Biological Function and Small Molecule Inhibitors of Histone Deacetylase 11

Targeting histone deacetylases for heart diseases